150
Participants
Start Date
June 30, 2014
Primary Completion Date
January 31, 2015
Study Completion Date
March 31, 2015
KPI-121
KPI-121 drug product will be supplied as 0.25% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
Placebo
Subjects randomized to placebo control arms will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
South Shore Eye Center, LLP, Wantagh
Total Eye Care, PA, Memphis
Abrams Eye Center, Cleveland
Price Vision Group, Indianapolis
Comprehensive Eye Care, Ltd. / Vision Research Institute, LLC, Washington
Ophthalmology Associates, St Louis
Whitsett Vision Group, Houston
Sall Research Medical Center, Artesia
North Valley Eye Medical Group, Mission Hills
Martel Eye Medical Group, Rancho Cordova
Eye Center of Southern CT, P.C., Hamden
Lead Sponsor
Kala Pharmaceuticals, Inc.
INDUSTRY